TORONTO, ON, March 18, 2014 - Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased to announce the addition of Dr. Dominique Dugourd to the Soricimed Executive Team as Vice President, Research & Development. In her new role, Dugourd will be adding her expertise, education and experience to further the development of our pipeline and position products for commercialization.
Dr. Dugourd brings 15 years of private sector R&D experience to Soricimed, having served in management positions, building and leading teams in both Therapeutics and Diagnostics fields. Dominique was most recently R&D manager at BD Diagnostics, developing class I and II IVD molecular diagnostics products and novel based infectious disease molecular diagnostic products. Previously she held leadership positions at MIGENIX Inc.
“I am thrilled to join a team dedicated to advancing the development and commercialization of both therapeutic and diagnostic products”, commented Dr. Dugourd. “I am looking forward to the future success of Soricimed because it has all of the core elements – great people, exciting technology and a strong mission to improve health.”
“With Dominique we found an excellent combination of scientific breadth and extensive industry experience including product development, project management, team development, IP, regulatory and commercialization”, stated Jack Stewart, Chief Scientific Officer, Soricimed Biopharma Inc. “She has a proven track record and will be a great addition to the Soricimed team and culture.”
“We are very pleased to have Dominique join our executive team”, added Paul Gunn, President and CEO, Soricimed Biopharma. “The addition of private sector experience is critical for Soricimed at this time, as we move toward more commercial partnerships and collaborations.”
Soricimed has developed anti-cancer agent SOR-C13, a targeted peptide derived from the venom of the northern short-tailed shrew. It works by inhibiting a non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast, prostate and others. It is currently being studied within a multicenter, open-label Phase I trial taking place at cancer centers in both Canada and the United States. Soricimed is hopeful that SOR-C13 could get to market in the next three to five years.
Soricimed Biopharma Inc. (@Soricimed), a private Canadian clinical stage company developing novel cancer therapeutics, diagnostics and a peptide drug conjugate platform, was created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin derivatives are the basis for Soricimed Biopharma Inc.’s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com.
Julie Fotheringham - Partner, Hageman Communications 416-951-7988 Julie.email@example.com